ReviewJournal of clinical medicine2026
Emerging Serological Biomarkers for Autoimmune Hepatitis.
Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Autoimmune hepatitis (AIH) lacks a disease-specific diagnostic biomarker, particularly for patients who present with acute onset, normal IgG levels, or seronegative profiles. Recent advances in high-throughput autoantibody profiling technologies have enabled the systematic discovery of novel AIH-associated autoantigens. This review summarizes emerging autoantibodies that have been identified through proteome-wide screening approaches, including human protein microarrays and phage immunoprecipitation sequencing. Particular attention is given to anti-docking protein 2 (DOK2) and anti-mitochondrial ribosomal protein S27 (MRPS27) antibodies, which have shown promising diagnostic performance. Importantly, the combined assessment of these autoantibodies markedly improves the diagnostic sensitivity for AIH and may be useful for screening or clinical triage, although its reduced specificity limits its use as a stand-alone confirmatory test. We also discuss how the integration of serological biomarkers with molecular pathology and spatial immune analysis may advance the understanding of AIH pathogenesis. These developments highlight the potential of proteome-wide autoantibody discovery to refine diagnostic strategies for AIH and provide new insights into disease mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.